Leiomyosarcoma treatment insights from tumor genetics
Official title: A retrospective and prospective study of leiomyosarcoma systemic therapy outcomes informed by tumor genomics
Funded at Sloan-Kettering Inst Can Research · NIH-11495322 · Data updated 2026-11-12
A study looks at how tumor genetics relate to how leiomyosarcoma patients respond to standard systemic therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 25, 2026 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $345,343 |
| NIH project number | 1R01FD008219-01A1 |
| Project ID | NIH-11495322 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults diagnosed with leiomyosarcoma (any primary site) who have metastatic disease and have received systemic therapy or are undergoing sequencing.
✕Less likely to help
Patients whose tumors do not show meaningful genetic associations with therapy response may not benefit from genotype-guided treatment changes.
What this research studies
This project will combine genomic data from hundreds of leiomyosarcoma patients with the therapies they have received for metastatic disease at two cancer centers. By linking next-generation sequencing results to treatment outcomes, researchers aim to identify genetic patterns that predict response or resistance. The study includes retrospective analysis of existing data and prospective sequencing of about 150 new patients per year to enrich understanding over several years. The goal is to translate genetic insights into more informed treatment choices for people with leiomyosarcoma.
Why it matters
Potential benefit: If successful, the findings could help doctors tailor therapies to a patient’s tumor genetics, potentially improving outcomes for leiomyosarcoma.
How similar studies have gone: Previous research has linked tumor genetics to treatment response in other cancers; applying this to leiomyosarcoma is promising but requires validation.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Maki, Robert G — Sloan-Kettering Inst Can Research
- Study coordinator: Maki, Robert G
Related research
Other NIH-funded projects on the same topics.
-
Genomic vulnerabilities in leiomyosarcoma: targeting DNA-PK pathways
This grant aims to find targeted ways to treat leiomyosarcoma by exploiting the tumor’s DNA repair weaknesses and testing biomarkers that may guide therapy.
-
Genetics and Genomics of Leiomyosarcoma: better understanding and new options for diagnosis and treatment
A large research program is exploring the genetic drivers of leiomyosarcoma to help develop better ways to diagnose and treat this cancer.
-
Targeting DNA repair weaknesses in leiomyosarcoma
This project tests drugs that block a DNA-repair enzyme to make leiomyosarcoma tumors more sensitive to treatment for people with metastatic LMS.
-
Understanding the genes behind leiomyosarcoma to improve diagnosis and treatment
This project looks at how inherited and tumor gene changes, especially TP53 and other DNA repair genes, affect people with leiomyosarcoma to help create better tests and therapies.
-
Developing a new mouse model for a rare type of uterine cancer
This study is creating special mice that have a type of uterine cancer called leiomyosarcoma, so researchers can learn more about the disease and find better treatments for people who have it.
-
Understanding genetic weaknesses in leiomyosarcoma
This study is looking at leiomyosarcoma, a tough type of cancer, to understand how certain genetic changes can affect how it responds to treatment, with the goal of finding better ways to target and treat this cancer for patients like you.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.